Names
Synribo® Omacetaxine mepesuccinateIndications and usage
Omacetaxine mepesuccinate is FDA approved for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).
The effectiveness of omacetaxine mepesuccinate was evaluated using a combined group of patients whose cancer progressed after previous treatment with two or more TKIs. All participants were treated with omacetaxine mepesuccinate.
Side effects needing medical attention
Low platelet counts, low red blood cell counts, low white blood cell counts, low level of lymphocytes, diarrhea, nausea, fatigue, weakness, injection site reaction, fever, infection, febrile neutropenia, constipation, vomiting, upper abdominal pain, peripheral edema, joint pain, pain in extremity, back pain, headache, insomnia, cough, nose bleed, hair loss, rash.